UNSPSC 51191537: Dehydrocholic acid

This classification denotes a cholagogue or choleretic agent with the molecular formula C24H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NH5000009I, chemically known as cholan-24-oic acid, 3,7,12-trioxo-, (5.beta.)- but generally known as dehydrocholic acid, which bears US NIH Compound Identifier 2975. European Medicines Agency schedules Dehydrocholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06945MIG. The term DEHYDROCHOLIC ACID is an International Non-Proprietary Name.

UNSPSC 51191537 Dehydrocholic acid is a Commodity code that captures chemical supply for municipal and regional water treatment and pharmaceutical distribution operations. State and local governments procuring under this code are sourcing both specialized treatment chemicals like sodium bisulfite for water pollution control facilities and generic pharmaceuticals and over-the-counter products for health-care and public-health distribution networks. The issuing bodies include municipal water departments, state health and procurement agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions.

Recent activity shows geographic spread across the Northeast and upper Midwest, with the City of Meriden, Connecticut soliciting sodium bisulfite for its Water Pollution Control Facility under IFB B027-15 with a due date of July 29, 2026, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issuing an RFP for generic multi-source pharmaceuticals and OTC products with a due date of March 26, 2026 and an effective contract date of July 1, 2026. The MMCAP procurement is notably broader in scope, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and mandating cGMP and Drug Supply Chain Security Act compliance, 3 percent administrative fees, and commercial general liability insurance of $5,000,000 per occurrence. The Meriden opportunity requires performance and payment bonds and $1,000,000 to $2,000,000 in general liability coverage. Both solicitations signal ongoing state and local demand for reliable chemical and pharmaceutical supply chains with robust vendor insurance, compliance, and reporting standards.